Publicaciones en colaboración con investigadores/as de Hospital General de Ciudad Real (9)

2018

  1. Circulating levels of sclerostin are associated with cardiovascular mortality

    PLoS ONE, Vol. 13, Núm. 6

2016

  1. Metabolomic profile related to cardiovascular disease in patients with type 2 diabetes mellitus: A pilot study

    Talanta, Vol. 148, pp. 135-143

  2. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?

    Endocrine, Vol. 52, Núm. 1, pp. 54-62

  3. Serum dickkopf1 (DKK1), bone metabolism and atherosclerotic disease in patients with type 2 diabetes

    Revista de Osteoporosis y Metabolismo Mineral, Vol. 8, Núm. 1, pp. 24-29

2015

  1. Relationship between proinflammatory and antioxidant proteins with the severity of cardiovascular disease in type 2 diabetes mellitus

    International Journal of Molecular Sciences, Vol. 16, Núm. 5, pp. 9469-9483

2014

  1. FGF23 in type 2 diabetic patients: Relationship with bone metabolism and vascular disease

    Diabetes Care

  2. Relationship of Dickkopf1 (DKK1) with Cardiovascular Disease and Bone Metabolism in Caucasian Type 2 Diabetes Mellitus

    PLoS ONE, Vol. 9, Núm. 11

2013

  1. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels

    Diabetes Care, Vol. 36, Núm. 6, pp. 1667-1674

2012

  1. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus

    Journal of Clinical Endocrinology and Metabolism, Vol. 97, Núm. 1, pp. 234-241